- /
- Supported exchanges /
- NASDAQ /
- SPRO.NASDAQ
Spero Therapeutics Inc (SPRO NASDAQ) stock market data APIs
Spero Therapeutics Inc Financial Data Overview
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Spero Therapeutics Inc data using free add-ons & libraries
Get Spero Therapeutics Inc Fundamental Data
Spero Therapeutics Inc Fundamental data includes:
- Net Revenue: 118 M
- EBITDA: 21 008 K
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-11
- EPS/Forecast: -0.5
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Spero Therapeutics Inc News
14 Cheap Penny Stocks to Buy According to Analysts
In this article, we will take a detailed look at the 14 Cheap Penny Stocks to Buy According to Analysts. For a quick overview of such stocks, read our article5 Cheap Penny Stocks to Buy According to ...
15 Cash-Rich Penny Stocks Hedge Funds Are Buying
In this article, we will take a detailed look at the15 Cash-Rich Penny Stocks Hedge Funds Are Buying. For a quick overview of such stocks, read our article 5 Cash-Rich Penny Stocks Hedge Funds Are Buy...
11 Hyper-Growth Stocks Billionaires Are Loading Up On
In this article, we will take a detailed look at the11 Hyper-Growth Stocks Billionaires Are Loading Up On. For a quick overview of such stocks, read our article 5 Hyper-Growth Stocks Billionaires Are ...
Spero Therapeutics, Inc. (NASDAQ:SPRO): Are Analysts Optimistic?
We feel now is a pretty good time to analyse Spero Therapeutics, Inc.'s (NASDAQ:SPRO) business as it appears the company may be on the cusp of a considerable accomplishment. Spero Therapeutics, Inc., ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.